Business Description
KalVista Pharmaceuticals Inc
NAICS : 325411
SIC : 2834
ISIN : US4834971032
Description
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 21.86 | |||||
| Equity-to-Asset | 0.83 | |||||
| Debt-to-Equity | 0.05 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -5.9 | |||||
| 3-Year EPS without NRI Growth Rate | -12.2 | |||||
| 3-Year FCF Growth Rate | -15.5 | |||||
| 3-Year Book Growth Rate | -22.7 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 36.84 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 17.85 | |||||
| 9-Day RSI | 28 | |||||
| 14-Day RSI | 33.08 | |||||
| 6-1 Month Momentum % | -19.23 | |||||
| 12-1 Month Momentum % | -16.83 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.87 | |||||
| Quick Ratio | 6.87 | |||||
| Cash Ratio | 6.13 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.3 | |||||
| Shareholder Yield % | 0.3 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -109.15 | |||||
| ROA % | -92.09 | |||||
| ROIC % | -845.47 | |||||
| ROC (Joel Greenblatt) % | -1842.76 | |||||
| ROCE % | -109.53 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.83 | |||||
| Price-to-Tangible-Book | 2.82 | |||||
| EV-to-EBIT | -1.88 | |||||
| EV-to-EBITDA | -1.89 | |||||
| EV-to-Forward-Revenue | 17.6 | |||||
| EV-to-FCF | -2.49 | |||||
| Price-to-Net-Current-Asset-Value | 3.02 | |||||
| Price-to-Net-Cash | 3.48 | |||||
| Earnings Yield (Greenblatt) % | -53.19 | |||||
| FCF Yield % | -28.43 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
KalVista Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | |||
| EPS (TTM) (€) | -3.405 | ||
| Beta | -0.3 | ||
| Volatility % | 60.41 | ||
| 14-Day RSI | 33.08 | ||
| 14-Day ATR (€) | 0.302335 | ||
| 20-Day SMA (€) | 8.7475 | ||
| 12-1 Month Momentum % | -16.83 | ||
| 52-Week Range (€) | 7.65 - 15 | ||
| Shares Outstanding (Mil) | 49.42 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
KalVista Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
KalVista Pharmaceuticals Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
KalVista Pharmaceuticals Inc Frequently Asked Questions
What is KalVista Pharmaceuticals Inc(STU:4XC1)'s stock price today?
The current price of STU:4XC1 is €7.65. The 52 week high of STU:4XC1 is €15.00 and 52 week low is €7.65.
When is next earnings date of KalVista Pharmaceuticals Inc(STU:4XC1)?
The next earnings date of KalVista Pharmaceuticals Inc(STU:4XC1) is 2025-03-11 Est..
Does KalVista Pharmaceuticals Inc(STU:4XC1) pay dividends? If so, how much?
KalVista Pharmaceuticals Inc(STU:4XC1) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers